| Autor: |
Lamparella N; Department of Medicine, Penn State Hershey Medical Center, 500 University Dr., Hershey, PA 17033, USA., Barochia A, Almokadem S |
| Jazyk: |
angličtina |
| Zdroj: |
Advances in experimental medicine and biology [Adv Exp Med Biol] 2013; Vol. 779, pp. 145-64. |
| DOI: |
10.1007/978-1-4614-6176-0_6 |
| Abstrakt: |
Non-small cell lung cancer represents a group of heterogeneous diseases. The last decade witnessed significant progress in improving our understanding of the biology of non-small cell lung cancer, which led to the identification of several genetic targets. Those genetic targets were utilized to explain clinical phenomena, such as the occurrence of non-small cell lung cancer in never-smokers, to predict response to conventional chemotherapy and biological agents, and to explain and predict resistance to therapy. The progress in the treatment of non-small cell lung cancer in the last few years was based on a new generation of population-enriched clinical trials that utilized genetic targets such as somatic EGFR mutations and ALK-EML4 mutations. In this review we will discuss the available information about the key genetic markers of non-small cell lung cancer and the pivotal clinical trials that validate the use of those genetic markers in non-small cell lung cancer patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
